Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The primary objective was to compare change in mean hemoglobin A1c (HbA1c) from baseline to the end of V-Go use. METHODS: This prospective, open-label, multicenter study recruited patients with type 2 diabetes (T2D) and suboptimal glycemic control (HbA1c ≥ 7%) across 28 centers. Efficacy analyses were conducted for all patients with a post-baseline HbA1c and results stratified based on prior antihyperglycemic medication therapies. Insulin dosing was at the discretion of the health care provider and the protocol did not mandate glycemic targets. Treatment satisfaction surveys were utilized to gain patient feedback on the use of V-Go. RESULTS: One hundred eighty-eight patients were enrolled in the study, among whom 140 patients had a valid post-baseline HbA1c and were included in the primary efficacy analysis. Use of V-Go resulted in a change of - 0.64%; (P = 0.003) in HbA1c from baseline, and in those prescribed insulin, the total daily dose of insulin was decreased by 12 units/day (P < 0.0001). Twenty-two patients (12%) reported hypoglycemic events (≤ 70 mg/dL), with an event rate of 1.51 events/patient/year. CONCLUSION: In a T2D population with suboptimal HbA1c, initiating V-Go therapy in a real-world setting significantly improved glycemic control and led to significant insulin dose reductions. ClinicalTrial.gov registry identifier: NCT01326598.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Ultra-rapid acting insulins can reduce postprandial glycemic peak, but this effect on long-term complications is unknown.1085,1086”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1086]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 1×
“The implementation of a rigorously followed basal insulin titration algorithm in the management of T2D has demonstrated good results in improving HbA1c [2], although higher doses of basal insulin have been shown to have diminishing returns.”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“7 out of 10), which is significant considering that regimen complexity and patient satisfaction can both impact patient compliance, which is critical to improving glycemic control [19].”
BackgroundGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297 · cited 1×
“Insulin is the most potent antihyperglycemic therapy, and adding basal insulin is the preferred method when insulin therapy is initiated [1].”
MethodSelf-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s007 · Cited by 179
Petrak, F., Stridde, E., Leverkus, F., Crispin, A. A., Forst, T., & Pfützner, A. (2007) · Diabetes Care · doi:10.2337/dc06-2042 · Cited by 84
Ginsberg, B. H. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818786513 · Cited by 60 · cited 1×
“Approximately 8 million people with diabetes are prescribed insulin in the United States, highlighting the importance of the devices that deliver insulin [18].”
BackgroundHow much is too much? Outcomes in patients using high‐dose insulin glargine
Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L. B., Vlajnic, A., & Rhinehart, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12747 · Cited by 48 · cited 1×
“5 units/kg did not result in further HbA1c or fasting plasma glucose improvement and increased the risk of hypoglycemia [3].”
BackgroundWinter, A., Lintner, M., & Knezevich, E. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815580361 · Cited by 30 · cited 1×
“To our knowledge, only two prospective studies [16, 17] have been published, and both are based on short-term use.”
BackgroundLajara, R., Davidson, J. A., NIKKEL, C. C., & Morris, T. L. (2016) · Endocrine Practice · doi:10.4158/ep151182.or · Cited by 25
Self-citation
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Metadata
- Authors
- Grunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P.
- Affiliations
- Oakland University (US)
- Touro College (US)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Nikkel, Carla
- Venue
- Drugs - Real World Outcomes
- Published
- 2019-12-12
- Volume
- 7
- Issue
- 1
- Pages
- 31-40
- ISSN
- 2198-9788 (ISSN-L)
- 2199-1154
- PMC
- PMC7060972
- OpenAlex
- W2995327439
- Cited by
- 19
- References
- 17
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs - Real World Outcomes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Valeritas
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, continuous insulin infusion, glycemic control, HbA1c, insulin dose reduction, hypoglycemia, multiple daily insulin injections, treatment satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study. https://app.cochat.ai/papers/10.1007/s40801-019-00173-8
- The paper
- Grunberger, G., Rosenfeld, C. R., Bode, B. W., Abbott, S. D., Nikkel, C., Shi, L., & Strange, P. (2020). Effectiveness of V-Go(®) for patients with type 2 diabetes in a real-world setting: A prospective observational study. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-019-00173-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.